Enhanced antitumour effect of liposomal daunorubicin using antibody-phospholipase C conjugates or fusion protein

International Journal of Oncology

Volumn 13, Issue 4, 1998, Pages 819-825

  Carter, Graham ^a   White, Patricia ^a   Fernie, Marie ^a   King, Susan ^a   McLean, Gordon ^a   Titball, Richard ^b   Carr, Frank J ^a  

^a MERCK KGAA   (Germany)

^b DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

Author keywords

Antibody; Daunorubicin; Liposome; Monoclonal; Phospholipase C

Indexed keywords

ANTIBODY CONJUGATE; DAUNORUBICIN; HYBRID PROTEIN; MONOCLONAL ANTIBODY; PHOSPHOLIPASE C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GRAFT; CELL PROLIFERATION; CONTROLLED STUDY; DRUG TARGETING; ENCAPSULATION; FEMALE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; XENOGRAFT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL; CARCINOEMBRYONIC ANTIGEN; CELL DIVISION; DAUNORUBICIN; HELA CELLS; HUMANS; IMMUNOGLOBULIN FRAGMENTS; LIPOSOMES; MICE; MICE, NUDE; PHOSPHOLIPASE C; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TUMOR CELLS, CULTURED;

EID: 0031666453     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.13.4.819     Document Type: Article

References (29)

1. Forssen EA and Tokes ZA: Attenuation of dermal toxicity of doxorubicin by liposome encapsulation. Cancer Treat Rep 67: 481-484, 1983.
2. Balazsovits JAE, Mayer LD, Bally MB, Cullis PR, McDonell M, Ginsberg RS and Falk RE: Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumour efficacy of doxorubicin. Cancer Chemother Pharmacol 23: 81-86, 1989.
3. Ranade VV: Drug delivery systems 1. Site-specific drug delivery using liposomes as carriers. J Cancer Pharmacol 29: 685-694, 1989.
4. Forssen EA, Coulter DM and Proffitt RT: Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. Cancer Res 52: 3255-3261, 1992.
5. Rahman YE, Hanson WR, Bharucha J, Ainsworth EJ and Jaroslow BN: Mechanisms of reduction of antitumor drug toxicity of liposome encapsulation. Ann NY Acad Sci 308: 325-341, 1978.
6. Forssen EA and Tokes ZA: Use of anionic liposomes for reduction of chronic doxorubicin-induced cardiotoxicity. Proc Natl Acad Sci USA 78: 1873-1877, 1981.
7. Rahman A, Kessler A, More N, Sikic B, Rowden G, Woolley P and Schein PS: Liposomal protection of adriamycin-induced cardiotoxicity in mice. Cancer Res 40: 1532-1537, 1980.
8. Gabizon A, Meshorer A and Barenholz Y: Comparative long-term study of the toxicities of free and liposome-associated doxorubicin in mice after intravenous administration. J Natl Cancer Inst 77:459-469, 1986.
9. Kaye SB, Boden JA and Ryman BE: The effect of liposome (phospholipid vesicle) entrapment of actinomycin-D and methotreaxate on the in vivo treatment of sensitive and resistant solid murine tumors. Eur J Cancer 17: 279-289, 1981.
10. Ganapathi R, Krishan A, Wodinsky I, Zubrod CG and Lesko LJ: Effect of cholesterol content on antitumor activity and toxicity of liposome-encapsulated 1-ß-D-arabinofuranosylcytosine in vivo. Cancer Res 40: 630-633, 1980.
11. Forssen EA and Ross ME: Daunoxome® treatment of solid tumors: preclinical and clinical investigations. J Liposome Res 4: 481-512, 1994.
12. Rutman RJ, Ritter CA, Avadhani NG and Hansel J: Liposomal potentiation of the antitumor activity of alkylating drugs. Cancer Treat Rep 60: 617-618, 1976.
13. Sunamoto J and Iwamoto K: Protein-coated and polysaccharide coated liposomes as drug carriers. Therapeutic drug carrier systems. CRC Crit Rev 2: 117-136, 1985.
14. Papahadjopoulos D and Gabizon A: Targeting of liposomes to tumor cells IH vivo. Ann NY Acad Sci 507: 64-67, 1987.
15. Ohta S, Igarashi S, Honda A, Sato S and Hanai N: Cytotoxicity of adriamycin-containing immunoliposomes targeted with antiganelioside monoclonal antibodies. Anticancer Res 13: 331-336, 1993.
16. Hesketh TR, Payne SN and Humphrey JH: Complement and phospholipase C lysis of lipid membranes. Immunology 23: 705-711, 1972.
17. Durrant LG, Robins RA and Baldwin RW: Flow cytometric screening of monoclonal antibodies for drug or toxin targeting to human cancer. J Natl Cancer Inst 81: 688-691, 1989.
18. Gullick WJ: Prevalence of aberrant expression of the epidermal growth-factor receptor in human cancers. Br Med Bull 47: 87-98, 1991.
19. Durrant LG, McDowell KM, Holmes RA and Liu DTY: Screening of monoclonal antibodies recognizing oncofetal antigens for isolation of trophoblasts from maternal blood for prenatal diagnosis. Prenat Diagn 14: 131-140, 1994.
20. Jones ST and Bendig MM: Rapid PCR-cloning of full length mouse immunoglobulin variable regions. Biotechnology 9: 88-89, 1991.
21. Titball RW, Hunter SEC, Martin KL, Morris BC, Shuttleworth AD, Rubidge T, Anderson DW and Kelly DC: Molecular cloning and nucleotide sequence of the alpha-toxin (phospholipase C) of Clostridiun perfringens. Infect Immun 57: 367-376, 1989.
22. Chovnick A, Schneider WP, Tso JY, Queen C and Chang CN: A recombinant membrane-acting immunotoxin. Cancer Res 51: 465-467, 1991.
23. Bragman KS, Heath TD and Papahadjopoulos D: Cytotoxicity of antibody-directed liposomes that recognize two receptors on K562 cells. J Natl Cancer Inst 73: 127-131, 1984.
24. Hashimoto Y, Sugawara M, Masuko T and Hojo H: Antitumor effect of actinomycin D entrapped in liposomes bearing subunits of tumor-specific monoclonal immunoglobulin M antibody. Cancer Res 43: 5328-5334, 1983.
25. Huang A, Kennel SJ and Huang L: Interactions of immunoliposomes with target cells. J Biol Chem 258: 14034-14040, 1983.
26. Marchy P and Leserman LD: Small liposomes are better than large liposomes for specific drug delivery in vitro. Biochim Biophys Acta730: 313-320, 1983.
27. Matthay KK, Heath TD and Papahadjopoulos D: Specific enhancement of drug delivery to AKR lymphoma by antibodytargeted small unilamellar vesicles. Cancer Res 44: 1880-1886, 1984.
28. Bagshawe KD, Springer CJ, Searle F, Antoniw P, Sharma S, Melton RG and Sherwood RP: A cytotoxic agent can be generated selectively at cancer sites. Br J Cancer 58: 700-703, 1988.
29. Riechmann L, Clark M, Waldmann H and Winter G: Reshaping human antibodies for therapy. Nature 322: 323-327, 1988.